This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

MarketVIEW: Herpes Simplex Virus Vaccines (therapeutic)

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Herpes Simplex Virus vaccines (therapeutic)

http://www.reportlinker.com/p0961700/MarketVIEW-Herpes-Simplex-Virus-vaccines-therapeutic.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Herpes Simplex Virus (HSV) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging.

Vaccine manufacturers have pursued the development of both prophylatic (PX) and therapeutic (TX) HSV vaccines albeit with little success to date. For therapeutic approaches a vaccine could reduce the frequency/duration of recurrences and lessen the need for long-term pharmacotherapy. Ideally the vaccine would also reduce transmission so having a wider public health benefit. 

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for a putative THERAPEUTIC (TX) HSV vaccine until 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. LO/BASE/HI target product profile (TPP) scenarios are included which examine the uptake of vaccines with differing clinical performance. A detailed review is also included on latest trends in disease epidemiology/dynamics.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL Contents – Summary presentation (MS PowerPoint based)Author's noteExecutive SummaryPoint(s) to note regarding vaccine pricing/usageCommercial model – key model outputsHSV TX vaccine: available market ($000s) to 2030 by scenarioHSV TX vaccine: demand (000s doses) to 2030 by scenarioHSV TX vaccine: available market ($000s) to 2030 (low scenario)HSV TX vaccine: available market ($000s) to 2030 (base scenario)HSV TX vaccine: available market ($000s) to 2030 (high scenario)HSV TX vaccine: available market ($000s) to 2030 by country (base scenario)HSV therapeutic vaccines: commercial model assumptionsCurrent management of genital herpesThe role of HSV TX vaccinesHSV TX vaccine target populations (scenario definition)HSV TX vaccine: target product profile(s)Model assumptions: populations/penetration rates/pricing/launch sequenceMarkets included in modelCommercial model assumptions per TPP (LO/BASE/HI)HSV TX vaccine segment analysisContribution of HSV-1 and HSV-2 to commercial valueHSV therapeutic vaccines: R&D pipelineCompetitor landscape: overviewHSV TX vaccine pipelineAgenusPreclinical programsHSV therapeutic vaccines: Review on latest epidemiologyHSV-1/HSV-2: overviewHSV surveillanceEpidemiology: UKEpidemiology: USEpidemiology: other marketsHSV-1 and HSV-2 seroprevalence studiesRole of HSV-1 as a cause of genital herpesClinical reactivation of HSV-1 and HSV-2Methodology: Calculating TX vaccine target populationsBibliographyAbout VacZine AnalyticsDisclaimerPAGES: 66 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based)Title sheetScenario definitionChart – valueChart – volumeVolume summaryValue summary (High price)Value summary (Base price)Value summary (Low price)Country worksheets ?USCanadaUKFranceSpainItalyGermanyOther EUJapanAustraliaSourcesHerpes database (UK)Herpes database (US)Diagnoses ratesUS NDTI diagnosesUK HPA diagnosesUK HPA by ageUS HSV-2 seroprevalenceBack pageWORKSHEETS = 30

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs